Adding Value with PI at Umicore
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
UCB SA (Incorporated with Limited Liability in Belgium) As Issuer
Base Prospectus dated 8 March 2021 UCB SA (incorporated with limited liability in Belgium) as Issuer EUR 5,000,000,000 Euro Medium Term Note Programme Due from one month from the date of original issue This base prospectus (the “Base Prospectus”) relating to the EUR 5,000,000,000 Euro Medium Term Note Programme (the “Programme”) of UCB SA, a limited liability company (société anonyme) incorporated under the laws of Belgium, having its registered office at Allée de la Recherche 60, B-1070 Brussels and registered with the Crossroads Bank for Enterprises under number 0403.053.608 (“UCB”, or the “Issuer”) is valid, for the purpose of the admission to trading and listing of the Notes (as defined below) on the regulated market of Euronext Brussels or on another regulated market in the European Economic Area (the “EEA”), for a period of twelve months from the date of approval. Any Notes issued under the Programme are issued subject to the provisions set out herein. Under the Programme, the Issuer, subject to compliance with all relevant laws, regulations and directives, may from time to time issue Euro Medium Term Notes (the “Notes”) as may be agreed between the Issuer and the relevant Dealer (as defined below). The minimum Specified Denomination of Notes shall be EUR 100,000 (or its equivalent in other currencies).The maximum aggregate nominal amount of Notes outstanding will not at any time exceed EUR 5,000,000,000 (or the equivalent in other currencies). This Base Prospectus has been approved as a base prospectus for the purposes of Article 8 of Regulation 2017/1129 (as amended, the “Prospectus Regulation”) on 8 March 2021 by the Belgian Financial Services and Markets Authority (the “FSMA”) in its capacity as competent authority in accordance with Article 20 of the Prospectus Regulation. -
Stronger Together Annual Report 2007/ 08 the NA Group
Stronger together Annual Report 2007/ 08 The NA Group Norddeutsche Affi nerie is the leading integrated copper group in Europe. Our core competence lies in the production and processing of copper, the material of the future. We are excellently represented all along the value added chain of copper from raw material processing and cathode production through to the production of copper products. We are also outstandingly positioned worldwide in the recycling of copper and other metals. Copper Production Copper Processing Cathodes, precious Shapes, wire rod, wires, metals and by-products strips and profi les In the Copper Production Segment we produce As an integrated copper group, we process our copper copper cathodes from copper concentrates and recy- cathodes into a variety of copper products, fi rst and cled raw materials. Both types of raw materials are foremost electrolytic copper wire rod for the cable and sourced internationally; recycled raw materials are wire industry. In addition, we produce continuous also procured in Germany. Our earnings are primarily cast shapes from cathodes for the market and for pro- determined by treatment and refi ning charges that cessing internally into pre-rolled strip as well as strips, are agreed with the raw material suppliers as the pro- shaped wires and profi les. Our revenues are deter- cessing fee. Our copper cathodes fulfi l the very high mined inter alia by processing fees that refl ect the quality requirements of the metal exchanges. The value added. Copper Production Segment also includes the produc- tion of precious metals, sulphuric acid, iron silicate products and other metal and chemical products from the by-elements of copper in the raw materials. -
Integrated Annual Report 2020
Amber, living with psoriasis INTEGRATED ANNUAL REPORT 2020 ADAPTING FOR BETTER CARE INTEGRATED ANNUAL REPORT 2020 ADAPTING FOR BETTER CARE Welcome to our Integrated Annual Report 2020! Our Integrated Annual Report 2020 – Adapting for Better Care – aims to provide all interested stakeholders with the best pos- sible information on how UCB is creating value for patients with severe diseases and about how we care for our employees, for communities, and for our planet, now and into the future. About this report This Integrated Annual Report 2020 includes the management report in accordance with article 12 of the Royal Decree of 14 November 2007 relating to the obligations of issuers of finan- cial instruments admitted to trading on a regulated market. All information required to be included in such management report pursuant to articles 3:6 and 3:32 of the Belgian Code of Com- panies and Associations (i.e. Corporate Governance Statement – Remuneration Report included -, Business Performance Review and UCB’s Statement on extra-financial1 information) is reported throughout all different sections of this Integrated Annual Re- port. This Integrated Annual Report together with the materiality assessment have been prepared in accordance with the Global Reporting Standards core option and extra-financial information is audited by a third party. 1 ‘Extra-financial’ is the term used by UCB for information commonly referred to as ‘non-financial’. UCB | Integrated Annual Report 2020 3 Index Key Figures 6 UCB At a Glance 8 Letter to our stakeholders -
2016 Dec Patricio Barrios RESUME
December 2016 RESUME – P. Barrios RESUME EDUCATION: BSc. Chemistry - University Seville, Spain MSc. Chemical Engineering - University Seville, Spain PhD. Chemistry - University Seville, Spain; Thesis: “Kinetics of the Copper Blow Stage during pyrometallurgical Copper-Making” (A Kinetic Model) Dipl. Environmental Eng. - Technical University Madrid, Spain Dipl. R&D Management - CSIC (High Counsel Scientist Research) Madrid, Spain Dipl. Business Administration -ESADE Barcelona, Spain, and The International Social Science Council Paris, France PROFESIONAL EXPERIENCE: January 2016 – Present: Aurubis AG; Principal Adviser – Primary Copper. Responsible to provide high level strategic advice to the EVP-Primary Copper BU which includes assisting on the overall direction and function of Business Development, participating on special projects, including liaison and development of key relationships with selected business partners. April 2008 – December 2015: Aurubis AG (new public company resulting from the merging of Cumerio and Norddeutsche Affinerie ,with operations and activities in 22 countries around Europe, North America and Asia, totaling 6400 employees and 13.8 Billion € revenues): Senior Vice President - Projects Primary Copper. Responsible for Primary Copper Business Unit’s growing projects, with main focus on new business opportunities and external projects. April 2006 – April 2008: Cumerio (public Belgian company resulting from the carve-out of the former Union Miniere’s Copper operations): Vice President Operations & ExCom Member. Full corporate responsibility for the Cumerio Group operations: Copper Refining BU and Copper Products BU with operations in Pirdop (Bulgaria), Olen (Belgium) and Avellino (Italy); totaling 1500 employees and 3.5 Billion € of revenues. 2005 – March 2006: Associated, as Senior Adviser- Non Ferrous Metals at Hatch Corporate Finance (HCF) International Advisers (formerly HB Advisers) –Hatch Group-; a London based leading corporate finance advisory firm focused exclusively on the metals and mining sectors worldwide. -
Dynavax Announces Full Enrollment of Phase II/III AIC Trial
Dynavax Announces Full Enrollment of Phase II/III AIC Trial BERKELEY, Calif., May 19 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today announced that its Phase II/III clinical trial of AIC for ragweed allergy, which started in late February 2004, has been fully enrolled. The double blind, placebo controlled study involves 462 subjects at 30 sites in the U.S. and will be completed over the next 18 months. The immunization schedule, consisting of six injections over six weeks, will be completed by June. The clinical trial is being conducted in collaboration with UCB Pharma, a European pharmaceutical company that markets XYZAL® and developed ZYRTEC®, the leading prescription anti- allergy drug worldwide. Dynavax and UCB signed a global licensing and commercialization agreement covering ragweed and grass allergy immunotherapies in February 2004. The primary endpoint of the Phase II/III ragweed study will be nasal symptoms scores after the second ragweed season in the late summer and early fall of 2005, with secondary endpoints assessing symptoms, medication use and quality of life in both the first and second year. A blinded interim analysis will be made in late 2004 to assess safety and the appropriateness of commencing a one-year Phase III trial in early 2005. "The collaboration with UCB has been very effective, with both organizations working diligently to advance our ragweed program," said Dr. Dino Dina, president and CEO of Dynavax. "The rapid enrollment of our ragweed trial, particularly given its size and stringent enrollment criteria, is an early indication of the level of interest that both investigators and patients have in this therapy. -
Lamotrigine Orally Disintegrating Tablet
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 3001-14 Program Step Therapy - Anticonvulsants Medication/Therapeutic Anticonvulsants – Class Depakote®, Depakote ER®, Felbatol, Keppra® , Keppra® XR®, Lamictal®, Lamictal XR®, Lamictal ODT®, lamotrigine extended-release, lamotrigine orally disintegrating tablet, Lyrica, Mysoline, Neurontin®, Onfi, Oxtellar™ XR*, Qudexy XR* (brand and authorized generic), Sabril, Spritam*, Topamax®, Trileptal®, Trokendi® XR*, Zonegran® P&T Approval Date 8/2010, 11/2010, 11/2011, 2/2013, 11/2013, 4/2014, 7/2014, 11/2014, 4/2015, 1/2016, 6/2016, 6/2017, 9/2018, 9/2019, 10/2020, 6/2021 Effective Date 9/1/2021; Oxford only: N/A 1. Background Step Therapy programs are utilized to encourage use of lower cost alternatives for certain therapeutic classes. a. Multi-Source Brand Products This program requires a member to try the A-rated generic prior to receiving coverage for Depakote, Depakote ER, Felbatol, Keppra, Keppra XR, Lamictal, Lamictal ODT, Lamictal XR, Lyrica, Mysoline, Neurontin, Onfi, Sabril, Topamax, Trileptal and Zonegran. There will be exceptions for members with a documented diagnosis of a seizure disorder. For members with a claim for at least a 14 day supply of the A-rated generic in the previous 6 months, the prescription will process automatically. b. Modified Release Products This program requires a member to try levetiracetam immediate release, levetiracetam extended-release, levetiracetam solution, lamotrigine immediate release, divalproex sodium delayed release, Depakote delayed release, generic valproic acid, Depakene formulations, Depakote sprinkles, divalproex sodium sprinkles, oxcarbazepine or Trileptal prior to coverage of their respective modified release formulations: lamotrigine extended-release, lamotrigine orally disintegrating tablet, Oxtellar XR*, Qudexy XR*, Spritam and Trokendi XR*. -
Official Journal C161
ISSN 1725-2423 Official Journal C 161 of the European Union Volume 51 English edition Information and Notices 25 June 2008 Notice No Contents Page II Information INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES Commission 2008/C 161/01 Non-opposition to a notified concentration (Case COMP/M.5032 — Roxel/Protac) (1) ......................... 1 2008/C 161/02 Non-opposition to a notified concentration (Case COMP/M.5094 — Nokia/Trolltech) (1) ..................... 1 IV Notices NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES Council 2008/C 161/03 Notification by Romania concerning visa reciprocity .................................................................... 2 2008/C 161/04 Notification by Romania concerning visa reciprocity .................................................................... 3 Commission 2008/C 161/05 Euro exchange rates ............................................................................................................... 4 2008/C 161/06 Final report of the Hearing Officer in Case COMP/M.4781 — Norddeutsche Affinerie/Cumerio (Pursuant to Articles 15 and 16 of Commission Decision 2001/462/EC, ECSC of 23 May 2001 on the terms of reference of Hearing Officers in certain competition proceedings — OJ L 162, 19.6.2001, p. 21) ............................. 5 EN (1) Text with EEA relevance (Continued overleaf) 1 Notice No Contents (continued) Page 2008/C 161/07 Opinion of the Advisory Committee on Mergers given at its meeting of 9 January 2008 regarding a draft decision relating to Case COMP/M.4781 — Norddeutsche -
4Oct200722045121 1Dec200517045043
4OCT200722045121 This prospectus (the ‘‘Prospectus’’) relates to the initial offering (the ‘‘Offering’’) to subscribe for up to A75 million of new common shares in Ablynx NV (the ‘‘Company’’ or ‘‘Ablynx’’), with VVPR strips (the ‘‘VVPR Strips’’). This amount of New Shares with VVPR Strips may be increased by up to 15 per cent, to an amount of A86.25 million (the ‘‘Increase Option’’, the new shares initially offered and the shares offered as a result of the possible exercise of the Increase Option jointly being referred to as the ‘‘New Shares’’). Any decision to exercise the Increase Option will be announced, at the latest, on the date the Offer Price is announced. JPMorgan and KBC Securities (the ‘‘Joint Global Coordinators’’) will be granted an over-allotment option by the Company (the ‘‘Over-allotment Option’’), exercisable as of the listing date (the ‘‘Listing Date’’) and until 30 days thereafter, corresponding to up to 15 per cent of the New Shares subscribed for in the Offering for the sole purpose of allowing the Joint Global Coordinators to cover over-allotments, if any. The existing shares covered by the Over-allotment Option (the ‘‘Additional Shares’’ and, together with the New Shares, the ‘‘Offered Shares’’) and the New Shares issued upon exercise of the Over-allotment Option, if any, will not have a separate VVPR Strip. The Offered Shares are offered to the public in Belgium (including to employees, consultants and independent directors of the Company in Belgium) and, pursuant to a private placement, to institutional investors, both within and outside Belgium and to employees, consultants and independent directors of the Company outside Belgium. -
Portfolio of Investments
PORTFOLIO OF INVESTMENTS Variable Portfolio – Partners International Value Fund, September 30, 2020 (Unaudited) (Percentages represent value of investments compared to net assets) Investments in securities Common Stocks 97.9% Common Stocks (continued) Issuer Shares Value ($) Issuer Shares Value ($) Australia 4.2% UCB SA 3,232 367,070 AMP Ltd. 247,119 232,705 Total 13,350,657 Aurizon Holdings Ltd. 64,744 199,177 China 0.6% Australia & New Zealand Banking Group Ltd. 340,950 4,253,691 Baidu, Inc., ADR(a) 15,000 1,898,850 Bendigo & Adelaide Bank Ltd. 30,812 134,198 China Mobile Ltd. 658,000 4,223,890 BlueScope Steel Ltd. 132,090 1,217,053 Total 6,122,740 Boral Ltd. 177,752 587,387 Denmark 1.9% Challenger Ltd. 802,400 2,232,907 AP Moller - Maersk A/S, Class A 160 234,206 Cleanaway Waste Management Ltd. 273,032 412,273 AP Moller - Maersk A/S, Class B 3,945 6,236,577 Crown Resorts Ltd. 31,489 200,032 Carlsberg A/S, Class B 12,199 1,643,476 Fortescue Metals Group Ltd. 194,057 2,279,787 Danske Bank A/S(a) 35,892 485,479 Harvey Norman Holdings Ltd. 144,797 471,278 Demant A/S(a) 8,210 257,475 Incitec Pivot Ltd. 377,247 552,746 Drilling Co. of 1972 A/S (The)(a) 40,700 879,052 LendLease Group 485,961 3,882,083 DSV PANALPINA A/S 15,851 2,571,083 Macquarie Group Ltd. 65,800 5,703,825 Genmab A/S(a) 1,071 388,672 National Australia Bank Ltd. -
205836Orig1s000 205837Orig1s000 205838Orig1s000
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 205836Orig1s000 205837Orig1s000 205838Orig1s000 ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS EXCLUSIVITY SUMMARY NDA #: NDA 205836 (oral tablets), NDA 205837 (injection 10 mg/mL) NDA 205838 (oral solution 10 mg/mL) SUPPL # HFD # Trade Name: BRIVIACT Generic Name: BRIVIACT (brivaracetam); 10, 25, 50, 75, and 100 mg oral tablets; injection (10 mg/mL); and oral solution (10 mg/mL) Applicant Name: UCB, Inc. Approval Date, If Known: February 19, 2016 PART I IS AN EXCLUSIVITY DETERMINATION NEEDED? 1. An exclusivity determination will be made for all original applications, and all efficacy supplements. Complete PARTS II and III of this Exclusivity Summary only if you answer "yes" to one or more of the following questions about the submission. a) Is it a 505(b)(1), 505(b)(2) or efficacy supplement? YES X NO If yes, what type? Specify 505(b)(1), 505(b)(2), SE1, SE2, SE3,SE4, SE5, SE6, SE7, SE8 505(b)(1) c) Did it require the review of clinical data other than to support a safety claim or change in labeling related to safety? (If it required review only of bioavailability or bioequivalence data, answer "no.") YES X NO If your answer is "no" because you believe the study is a bioavailability study and, therefore, not eligible for exclusivity, EXPLAIN why it is a bioavailability study, including your reasons for disagreeing with any arguments made by the applicant that the study was not simply a bioavailability study. If it is a supplement requiring the review of clinical data but it is not an effectiveness supplement, describe the change or claim that is supported by the clinical data: Reference ID: 3888400 Page 1 d) Did the applicant request exclusivity? YES X NO New moiety exclusivity requested If the answer to (d) is "yes," how many years of exclusivity did the applicant request? Applicant did not specify. -
Celltech, a Sound Strategic Acquisition Neutral
UCB 8 June 2004 Celltech, a sound strategic acquisition Pharmaceuticals & Biotechnology Current price € 39.90 Neutral Belgium Target price € 42.00 Rating unchanged 118 FY/e 31.12 2003 2004E 2005E 2006E 40 Sales (€ m) 2,966 3,107 3,492 3,885 110 36 EBITDA (€ m) 647 672 810 948 102 Pre-Tax* (€ m) 485 453 486 621 32 94 Adj EPS* (€) 2.32 2.21 2.46 3.09 28 86 EPS (€) 2.32 1.83 1.70 2.32 DPS (€) 0.82 0.85 0.88 0.92 24 78 P/E* (x) 17.2 18.1 16.2 12.9 20 70 Yield (%) 2.1 2.1 2.2 2.3 JJSONJFMM Price Rel. to index (RHS) EV/EBITDA (x) 9.2 12.1 10.1 8.7 Source: Thomson Financial Datastream Source: KBC Securities *Adjusted for goodwill and exceptionals Reuters UCBBt.BR Bloomberg UCB BB UCB’s share price hasn’t stopped soaring since the www.ucb-group.com acquisition of Celltech. Although we are positive about this Market Cap € 5,823m strategic acquisition, we think that the upside potential is Shares outst. 145.9m now virtually exhausted. Volume (daily) € 10.6m Free float 59% • From a strategic standpoint, Celltech’s acquisition is an enormous step forward, reinforcing UCB’s Pharma pipeline Next corporate event and management team. But the road to positive returns is General Assembly FY03 on 8 June 2004 still long and risky, so UCB still deserves a discount to Performance over 1m 3m 12m average Pharma ratios. Absolute 14% 31% 45% In technical terms, the merger should be positive as the Rel. -
FORM 8-K PDL Biopharma, Inc
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 2, 2011 PDL BioPharma, Inc. (Exact name of Company as specified in its charter) 000-19756 (Commission File Number) Delaware 94-3023969 (State or Other Jurisdiction of (I.R.S. Employer Identification No.) Incorporation) 932 Southwood Boulevard Incline Village, Nevada 89451 (Address of principal executive offices, with zip code) (775) 832-8500 (Company’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 8.01 Other Events. PDL BioPharma, Inc. Resolves Patent Disputes with UCB Pharma SA On February 7, 2011, PDL BioPharma, Inc. (“PDL”) and UCB SA, on behalf of its affiliate UCB Pharma S.A. (“UCB”), jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between the parties, including those relating to UCB’s pegylated humanized antibody fragment, Cimzia® (certoluzimab pegol), and PDL’s Queen et al.